eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

Rhea-AI Summary

eXoZymes (NASDAQ:EXOZ), a company specializing in AI-engineered enzymes for sustainable feedstock transformation into nutraceuticals, medicines, and essential chemicals, has announced a webinar scheduled for Monday, May 12, 2025, at 5:00 PM Eastern Time. The event will cover the company's first quarter 2025 results and provide updates on their newly formed subsidiary, NCTx.

CEO Michael Heltzen will lead the presentation alongside management team members, discussing recent developments, ongoing initiatives, and upcoming milestones. The webinar will include a Q&A session and can be accessed through pre-registration or the company's investor relations website.

MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first quarter of 2025, as well as share more details around the newly formed purpose-built subsidiary, NCTx.

Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.

Investors can pre-register now for the webinar HERE. The live webinar can also be accessed on the day of the event through eXoZymes' investor relations website at https://exozymes.com/investor#webinar

About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce chemical compounds, enabling the company's partners to replace traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.

Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.

While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.

Learn more on exozymes.com

eXoZymes Safe Harbor

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

Investor relations contact
Email: ir@exozymes.com

eXoZymes media contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com

SOURCE: eXoZymes

View the original press release on ACCESS Newswire

FAQ

When is eXoZymes (EXOZ) Q1 2025 earnings webinar?

eXoZymes (EXOZ) will host its Q1 2025 earnings webinar on Monday, May 12, 2025, at 5:00 PM Eastern Time.

What will be discussed in the EXOZ Q1 2025 webinar?

The webinar will cover Q1 2025 results, updates on the new NCTx subsidiary, recent developments, ongoing initiatives, and upcoming milestones, followed by a Q&A session.

Who will present at the eXoZymes (EXOZ) Q1 2025 earnings call?

CEO Michael Heltzen will lead the presentation, accompanied by select members of the management team.

How can investors access the EXOZ Q1 2025 earnings webinar?

Investors can pre-register for the webinar or access it through eXoZymes' investor relations website at https://exozymes.com/investor#webinar